Liraglutide
Regulatory milestones approvals, filings & regulatory actions · 11 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (4) | US (FDA) | SAXENDA | — | 2017-04-26 – 2020-12-04 | fda.gov ↗ |
| Label expansions (5) | US (FDA) | VICTOZA | — | 2010-12-22 – 2019-06-17 | fda.gov ↗ |
| Approved | US (FDA) | VICTOZA | — | 2010-01-25 | fda.gov ↗ |
| Approved | EU (EMA) | Victoza | — | 2009-06-30 | europa.eu ↗ |
Trials 276 · started per year
Also used as a comparator or background therapy in 136 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT05794581 Comparator | Mar 2023 → Mar 2024 | type 1 diabetes mellitus | Carmot Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05444569 Background | Aug 2022 → Feb 2023 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04311411 Comparator | Aug 2020 → Dec 2022 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03757130 Background | Nov 2018 → Dec 2019 | obesity disorder | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT03115099 Comparator | May 2017 → Apr 2018 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01982630 Comparator | Nov 2013 → Oct 2014 | diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT02140983 Comparator | Aug 2013 → Feb 2017 | dementia | Stanford University | Completed | No outcome recorded |
| Phase 1 | NCT01870297 Background | Jun 2013 → Dec 2014 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01319240 Comparator | Mar → May 2011 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 227 trials | ||||||
| Phase 2 | NCT06976619 Comparator | Oct 2025 → Oct 2028 expected | type 1 diabetes mellitus, type 2 diabetes mellitus | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 2 | NCT05111912 Comparator | Nov 2021 → Nov 2022 | obesity disorder | Sciwind Biosciences APAC CO Pty. Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT03856047 Comparator | Mar 2019 → Mar 2020 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT03555994 Comparator | May 2018 → Apr 2021 | type 2 diabetes mellitus | MedImmune LLC | Completed | No outcome recorded |
| Phase 2 | NCT03486392 Comparator | Mar 2018 → Mar 2019 | obesity disorder | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT03235050 Comparator | Aug 2017 → May 2018 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT03158805 Comparator | Apr 2017 → Oct 2022 | bipolar disorder, obesity disorder | Lindner Center of HOPE | Completed | No outcome recorded |
| Phase 2 | NCT02953665 Comparator | Apr 2017 → Aug 2022 | Parkinson disease | Cedars-Sinai Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT02973321 Comparator | Dec 2016 → Dec 2017 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT02908087 Comparator | Mar 2016 → May 2021 | type 1 diabetes mellitus | University of Oulu | Completed | No outcome recorded |
| Phase 2 | NCT02898506 Comparator | Mar 2016 → Jun 2021 | type 1 diabetes mellitus | University of Oulu | Completed | No outcome recorded |
| Phase 2 | NCT02647944 Comparator | Dec 2015 → Dec 2016 | obesity disorder | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT02611232 Comparator | Dec 2015 → Jun 2024 | type 1 diabetes mellitus | University of Oulu | Unknown | No outcome recorded |
| Phase 2 | NCT02617654 Comparator | Nov 2015 → Sep 2020 | type 1 diabetes mellitus | Per-Ola Carlsson | Completed | No outcome recorded |
| Phase 2 | NCT02453711 Comparator | Oct 2015 → Mar 2017 | metabolic disease, obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT02461589 Comparator | Sep 2015 → Oct 2016 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT02492763 Comparator | Jul 2015 → Apr 2017 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 2 | NCT02408705 Comparator | Jan 2015 → May 2016 | type 1 diabetes mellitus | Medical University of Graz | Completed | No outcome recorded |
| Phase 2 | NCT02284230 Comparator | Dec 2014 → Aug 2015 | chronic renal failure syndrome, prediabetes syndrome | Bo Feldt-Rasmussen | Withdrawn | No outcome recorded |
| Phase 2 | NCT02205528 Comparator | Aug 2014 → Sep 2015 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT02057172 Comparator | Jan → Oct 2014 | type 2 diabetes mellitus | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 2 | NCT02315001 Comparator | Jan 2014 → Mar 2015 | intermediate coronary syndrome, myocardial ischemia | King's College London | Completed | No outcome recorded |
| Phase 2 | NCT01800968 Comparator | Apr 2013 → Oct 2015 | heart failure | Duke University | Completed | No outcome recorded |
| Phase 2 | NCT01725126 Background | Feb → Sep 2013 | obesity disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01755416 Comparator | Jan 2013 → Jan 2015 | type 1 diabetes mellitus | Albert Einstein College of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT01596504 Comparator | May 2012 → Jul 2013 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT01175473 Comparator | Aug → Nov 2010 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01879917 Comparator | Feb 2014 → Aug 2018 | type 1 diabetes mellitus | Hvidovre University Hospital | Completed | No outcome recorded |
| Phase 336 trials | ||||||
| Phase 3 | NCT05360147 Comparator | Jan → Apr 2021 | type 2 diabetes mellitus | Third Military Medical University | Completed | No outcome recorded |
| Phase 3 | NCT04057261 Comparator | Nov 2020 → Aug 2022 | cardiovascular disorder, type 2 diabetes mellitus | RWTH Aachen University | Withdrawn | No outcome recorded |
| Phase 3 | NCT04373967 Comparator | Apr 2020 → Dec 2021 | type 2 diabetes mellitus | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT03986008 Comparator | Dec 2019 → Dec 2021 | obesity disorder | Xiangya Hospital of Central South University | Unknown | No outcome recorded |
| Phase 3 | NCT04074161 Comparator | Sep 2019 → Mar 2021 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT03707171 Comparator | Oct 2018 → Feb 2019 | type 2 diabetes mellitus | Third Military Medical University | Completed | No outcome recorded |
| Phase 3 | NCT03279731 Comparator | Sep 2017 → Sep 2019 | binge eating disorder | Kelly Allison | Terminated | No outcome recorded |
| Phase 3 | NCT03191396 Comparator | Jun 2017 → Jul 2018 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT03115424 Comparator | Jun 2017 → Oct 2023 | obesity disorder | Mayo Clinic | Completed | No outcome recorded |
| Phase 3 | NCT03018028 Comparator | Jan 2017 → Jan 2018 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT02863419 Comparator | Aug 2016 → Aug 2017 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT02787551 Comparator | Jul 2016 → May 2018 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT02638805 Background | Dec 2015 → Oct 2017 | type 2 diabetes mellitus | Intarcia Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT02518945 Comparator | Aug → Dec 2015 | type 1 diabetes mellitus | University at Buffalo | Completed | No outcome recorded |
| Phase 3 | NCT02423824 Comparator | May 2015 → Apr 2016 | bipolar disorder, major depressive disorder | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 3 | NCT02654665 Comparator | Mar 2014 → Dec 2017 | NAFLD1, metabolic dysfunction-associated steatohepatitis | Changi General Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02016846 Comparator | Jan 2014 → Jan 2015 | hyperglycemia | Rabin Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT01937598 Background | Aug 2013 → Apr 2014 | type 2 diabetes mellitus | Michael A. Nauck | Completed | No outcome recorded |
| Phase 3 | NCT01794143 Comparator | May 2013 → Apr 2021 | type 2 diabetes mellitus | GRADE Study Group | Completed | No outcome recorded |
| Phase 3 | NCT01779362 Comparator | Apr 2013 → Feb 2019 | prediabetes syndrome, type 2 diabetes mellitus | RISE Study Group | Completed | No outcome recorded |
| Phase 3 | NCT01847313 Comparator | Apr 2013 → Nov 2015 | diabetic kidney disease | Karl Neff | Completed | No outcome recorded |
| Phase 3 | NCT02092896 Comparator | Mar 2013 → Oct 2014 | type 1 diabetes mellitus | Hvidovre University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01733758 Comparator | Feb 2013 → Jun 2014 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01753362 Comparator | Dec 2012 → Dec 2017 | type 1 diabetes mellitus | University at Buffalo | Completed | No outcome recorded |
| Phase 3 | NCT01722240 Comparator | Nov 2012 → Jan 2019 | type 1 diabetes mellitus | University at Buffalo | Completed | No outcome recorded |
| Phase 3 | NCT01722266 Comparator | Nov 2012 → Apr 2014 | type 1 diabetes mellitus | University at Buffalo | Completed | No outcome recorded |
| Phase 3 | NCT01722227 Comparator | Nov 2012 → Nov 2017 | type 1 diabetes mellitus | University at Buffalo | Withdrawn | No outcome recorded |
| Phase 3 | NCT01664247 Background | Oct 2012 → Dec 2013 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01628445 Comparator | Aug 2012 → Nov 2015 | type 2 diabetes mellitus | University of Manitoba | Terminated | No outcome recorded |
| Phase 3 | NCT01624259 Comparator | Jun 2012 → Nov 2013 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01558271 Comparator | Mar 2012 → Oct 2013 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT02417103 Comparator | Dec 2011 → Sep 2016 | obesity disorder | University Medical Center Hamburg-Eppendorf | Terminated | No outcome recorded |
| Phase 3 | NCT01296412 Comparator | Mar 2011 → Feb 2012 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01128894 Comparator | May 2010 → Sep 2011 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01029886 Comparator | Jan 2010 → Jan 2011 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT01784965 Comparator | Dec 2009 → Dec 2012 | prediabetes syndrome | Stanford University | Completed | No outcome recorded |
| Phase 442 trials | ||||||
| Phase 4 | NCT07301437 Comparator | May 2026 → Aug 2027 expected | — | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07325435 Comparator | Dec 2024 → Dec 2027 expected | type 2 diabetes mellitus | MaryAnn Banerji | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06449235 Comparator | Sep 2024 → Apr 2025 overdue | type 2 diabetes mellitus | Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06533527 Comparator | Jul 2024 → May 2025 | gastroparesis, obesity disorder, type 2 diabetes mellitus | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 4 | NCT06374875 Comparator | Jul 2024 → May 2029 expected | NAFLD1, fibrotic liver disease, metabolic dysfunction-associated steatohepatitis, obesity disorder | Ali Aminian | Recruiting | No outcome recorded |
| Phase 4 | NCT05812183 Background | Jul 2023 → Feb 2025 | — | University of California, Los Angeles | Withdrawn | No outcome recorded |
| Phase 4 | NCT05681299 Comparator | May 2023 → Apr 2028 expected | pituitary deficiency | Columbia University | Recruiting | No outcome recorded |
| Phase 4 | NCT05579249 Comparator | Jan 2023 → Nov 2024 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT05390892 Comparator | Sep 2022 → Mar 2029 expected | atherosclerotic cardiovascular disease, type 2 diabetes mellitus | Brigham and Women's Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT04657939 Comparator | Dec 2020 → Oct 2022 | type 2 diabetes mellitus | University of Leeds | Completed | No outcome recorded |
| Phase 4 | NCT04575194 Comparator | Sep 2020 → Sep 2022 | hypertensive disorder, obesity disorder | National and Kapodistrian University of Athens | Unknown | No outcome recorded |
| Phase 4 | NCT03955575 Comparator | Mar 2019 → Mar 2021 | malabsorption syndrome | Filip Krag Knop | Completed | No outcome recorded |
| Phase 4 | NCT03642600 Comparator | Feb 2019 → Feb 2020 | metabolic syndrome X, obesity disorder, polycystic ovary syndrome | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
| Phase 4 | NCT04046822 Comparator | Jan 2019 → Jan 2020 | obesity disorder | Federico II University | Unknown | No outcome recorded |
| Phase 4 | NCT03260881 Comparator | Sep 2018 → Sep 2024 | coronary artery disorder, type 2 diabetes mellitus | University of Miami | Completed | No outcome recorded |
| Phase 4 | NCT03466021 Comparator | Jan 2018 → May 2020 | chronic obstructive pulmonary disease | Claus Bogh Juhl | Completed | No outcome recorded |
| Phase 4 | NCT02911818 Comparator | Sep 2016 → Nov 2018 | obesity disorder | University of Pennsylvania | Completed | No outcome recorded |
| Phase 4 | NCT02488057 Comparator | May 2016 → Mar 2019 | prediabetes syndrome | Ohio State University | Completed | No outcome recorded |
| Phase 4 | NCT02655770 Comparator | Feb 2016 → Dec 2019 | diastolic heart failure, type 2 diabetes mellitus | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 4 | NCT02660047 Comparator | Aug 2015 → Mar 2018 | cardiovascular disorder, fatty liver disease, metabolic syndrome X, type 2 diabetes mellitus | Leiden University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT03619330 Comparator | Dec 2014 → Aug 2015 | hypogonadism, obesity disorder | University Medical Centre Ljubljana | Completed | No outcome recorded |
| Phase 4 | NCT01966978 Comparator | Nov 2014 → Dec 2017 | type 2 diabetes mellitus | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT02299388 Comparator | Oct 2014 → Nov 2016 | hypertensive disorder, type 2 diabetes mellitus | Tulane University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT03353948 Comparator | Sep 2014 → May 2016 | female infertility, obesity disorder, polycystic ovary syndrome | University Medical Centre Ljubljana | Completed | No outcome recorded |
| Phase 4 | NCT02147925 Comparator | Aug 2014 → Apr 2017 | NAFLD1 | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 4 | NCT03068065 Comparator | May → Nov 2014 | NAFLD1, type 2 diabetes mellitus | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Completed | No outcome recorded |
| Phase 4 | NCT03034941 Comparator | Apr 2014 → Dec 2016 | obesity disorder, polycystic ovary syndrome | University Medical Centre Ljubljana | Completed | No outcome recorded |
| Phase 4 | NCT02073929 Comparator | Mar 2014 → Dec 2015 | cardiovascular disorder, polycystic ovary syndrome | Jens Faber | Completed | No outcome recorded |
| Phase 4 | NCT02187250 Comparator | Mar → Jun 2014 | obesity disorder, polycystic ovary syndrome | University Medical Centre Ljubljana | Completed | No outcome recorded |
| Phase 4 | NCT02041234 Comparator | Feb 2014 → Dec 2020 | type 2 diabetes mellitus | Khoo Teck Puat Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02483299 Comparator | Jan 2014 → Apr 2015 | obesity disorder, polycystic ovary syndrome | University Medical Centre Ljubljana | Completed | No outcome recorded |
| Phase 4 | NCT01761318 Comparator | Nov 2013 → Mar 2016 | cardiovascular disorder, fatty liver disease, metabolic syndrome X, type 2 diabetes mellitus | Leiden University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01931982 Comparator | May 2013 → Apr 2014 | coronary microvascular disorder, type 2 diabetes mellitus | Bispebjerg Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01790308 Comparator | Feb 2013 → Dec 2014 | type 2 diabetes mellitus | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 4 | NCT01638260 Comparator | Oct 2012 → Nov 2013 | type 2 diabetes mellitus | Maastricht University Medical Center | Terminated | No outcome recorded |
| Phase 4 | NCT01597531 Comparator | Jun 2012 → Jun 2014 | type 2 diabetes mellitus | East Carolina University | Terminated | No outcome recorded |
| Phase 4 | NCT01595789 Comparator | May 2012 → Oct 2014 | coronary artery disorder, type 2 diabetes mellitus | Haugaard, Steen Bendix, M.D., DMSc | Completed | No outcome recorded |
| Phase 4 | NCT01505673 Comparator | Jan 2012 → Jun 2016 | obesity disorder, type 2 diabetes mellitus | Ildiko Lingvay | Completed | No outcome recorded |
| Phase 4 | NCT01911468 Comparator | Nov 2011 → Oct 2012 | obesity disorder, polycystic ovary syndrome | University Medical Centre Ljubljana | Completed | No outcome recorded |
| Phase 4 | NCT01394341 Comparator | Sep 2011 → Oct 2013 | end stage renal failure, type 2 diabetes mellitus | Bo Feldt-Rasmussen | Completed | No outcome recorded |
| Phase 4 | NCT01695109 Comparator | Nov 2010 → Feb 2012 | — | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT01117350 Comparator | Jul 2010 → Oct 2012 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase not applicable21 trials | ||||||
| — | NCT06836284 Background | Feb 2026 → Apr 2027 expected | — | Karolinska Institutet | Recruiting | No outcome recorded |
| — | NCT06256419 Background | Jan 2024 → Jan 2028 expected | type 2 diabetes mellitus | The Affiliated Hospital of Xuzhou Medical University | Recruiting | No outcome recorded |
| — | NCT05705388 Comparator | Jan 2023 → Jan 2025 | obesity disorder | Emirates Health Services (EHS) | Unknown | No outcome recorded |
| — | NCT05268627 Comparator | Jan 2022 → Jan 2023 | obesity disorder | Mansoura University | Unknown | No outcome recorded |
| — | NCT04324229 Comparator | Feb 2020 → Sep 2024 overdue | gestational diabetes | Turku University Hospital | Active not recruiting | No outcome recorded |
| — | NCT04829903 Comparator | Jan 2020 → Mar 2021 | obesity disorder, type 2 diabetes mellitus | Corporacion Parc Tauli | Completed | No outcome recorded |
| — | NCT03948347 Comparator | Jun 2019 → Dec 2023 | transient ischemic attack, type 2 diabetes mellitus | First Affiliated Hospital of Jinan University | Unknown | No outcome recorded |
| — | NCT03961659 Comparator | May 2019 → Aug 2020 | cognitive impairment with or without cerebellar ataxia, obesity disorder, type 2 diabetes mellitus | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Unknown | No outcome recorded |
| — | NCT02879409 Background | Nov 2016 → Oct 2023 overdue | type 2 diabetes mellitus | Weill Cornell Medical College in Qatar | Active not recruiting | No outcome recorded |
| — | NCT02930265 Comparator | Sep 2016 → Feb 2018 | cardiomyopathy | Chinese PLA General Hospital | Unknown | No outcome recorded |
| — | NCT02777073 Comparator | Mar → Dec 2016 | type 1 diabetes mellitus | University at Buffalo | Completed | No outcome recorded |
| — | NCT03010683 Comparator | Nov 2015 → Jun 2017 | coronary artery disorder, type 2 diabetes mellitus | University of Athens | Completed | No outcome recorded |
| — | NCT02324842 Comparator | Nov 2014 → Mar 2018 | type 2 diabetes mellitus | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| — | NCT02244164 Comparator | Oct 2014 → Feb 2023 | type 2 diabetes mellitus | Erasme University Hospital | Terminated | No outcome recorded |
| — | NCT02138045 Comparator | May 2014 → Feb 2017 | type 1 diabetes mellitus | Aalborg University Hospital | Completed | No outcome recorded |
| — | NCT01677104 Comparator | Aug 2012 → Jul 2014 | obesity disorder, type 2 diabetes mellitus | Katarina Kos | Completed | No outcome recorded |
| — | NCT01469351 Comparator | Jan 2012 → Apr 2013 | Alzheimer disease | University of Aarhus | Completed | No outcome recorded |
| — | NCT01472640 Comparator | Nov 2011 → Sep 2015 | heart failure, hyperglycemia | Flyvbjerg, Allan, DMSc | Completed | No outcome recorded |
| — | NCT01460069 Comparator | Oct 2011 → May 2013 | psoriasis | Annesofie Faurschou | Completed | No outcome recorded |
| — | NCT01451905 Comparator | Aug 2011 → Dec 2012 | — | University Hospital, Gentofte, Copenhagen | Unknown | No outcome recorded |
| — | NCT01740921 Comparator | Jan 2011 → Dec 2015 | type 2 diabetes mellitus | Royal Devon and Exeter NHS Foundation Trust | Completed | No outcome recorded |
Press releases naming this drug 93 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-08-28 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss tevapharm.com ↗ |
| 2025-08-28 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss tevapharm.com ↗ |
| 2024-06-24 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United States tevapharm.com ↗ |
| 2019-03-18 | Novo Nordisk A/S | Novo Nordisk settles US patent litigation case on Victoza® (liraglutide) with Teva novonordisk.com ↗ |
| 2018-11-22 | Novo Nordisk A/S | Oral semaglutid giver større reduktioner i både langtidsblodsukker og vægt sammenlignet med Victoza® hos japanere med type 2-diabetes novonordisk.com ↗ |
| 2018-11-22 | Novo Nordisk A/S | Oral semaglutide demonstrates greater reductions in both HbA1c and body weight compared to Victoza® in Japanese people with type 2 diabetes novonordisk.com ↗ |
| 2018-06-20 | Novo Nordisk A/S | Oral semaglutid viser statistisk signifikant større reduktioner i langtidsblodsukker og vægt sammenlignet med Victoza® og sitagliptin i PIONEER 4 og 7 novonordisk.com ↗ |
| 2018-06-20 | Novo Nordisk A/S | Oral semaglutide shows statistically significantly greater reductions in HbA1c and weight compared to Victoza® and sitagliptin in the PIONEER 4 and 7 trials novonordisk.com ↗ |
| 2017-08-25 | Novo Nordisk A/S | Victoza® approved in the US as the only type 2 diabetes treatment indicated to reduce the risk of major adverse cardiovascular events novonordisk.com ↗ |
| 2017-08-25 | Novo Nordisk A/S | Victoza® godkendt i USA som eneste behandling af type 2-diabetes med indikation til at nedsætte risikoen for alvorlige kardiovaskulære hændelser novonordisk.com ↗ |
| 2017-07-27 | Novo Nordisk A/S | Novo Nordisk A/S: Victoza® has been approved in the EU as the only GLP-1 with a label to include prevention of cardiovascular events novonordisk.com ↗ |
| 2017-07-27 | Novo Nordisk A/S | Novo Nordisk A/S: Victoza® godkendt i EU som eneste GLP-1 med indlægsseddel, der omfatter forebyggelse af kardiovaskulære hændelser novonordisk.com ↗ |
| 2017-06-23 | Novo Nordisk A/S | Novo Nordisk A/S: CHMP adopts positive opinion for EU label update of Victoza® based on the LEADER trial novonordisk.com ↗ |
| 2017-06-23 | Novo Nordisk A/S | Novo Nordisk A/S: CHMP afgiver positiv udtalelse om opdatering af indlægssedlen for Victoza® i EU baseret på LEADER-studiet novonordisk.com ↗ |
| 2017-06-22 | Novo Nordisk A/S | Novo Nordisk A/S: CHMP støtter opdatering af indlægssedlen for Saxenda® i EU baseret på LEADER-studiet novonordisk.com ↗ |
| 2017-06-22 | Novo Nordisk A/S | Novo Nordisk A/S: CHMP endorses EU label update of Saxenda® based on the LEADER trial novonordisk.com ↗ |
| 2017-06-20 | Novo Nordisk A/S | Novo Nordisk receives positive 17-2 vote from FDA Advisory Committee that Victoza® provides substantial evidence of cardiovascular risk reduction in patients with type 2 diabetes novonordisk.com ↗ |
| 2017-06-20 | Novo Nordisk A/S | Novo Nordisk får positiv 17-2 afstemning fra FDA's rådgivende komite om, at Victoza® giver væsentlig dokumentation for nedsættelse af kardiovaskulær risiko hos mennesker med type 2-diabetes novonordisk.com ↗ |
| 2017-06-16 | Novo Nordisk A/S | FDA offentliggør briefingmateriale forud for møde i rådgivende komite om opdatering af indlægssedlen for Victoza® novonordisk.com ↗ |
| 2017-06-16 | Novo Nordisk A/S | FDA posts briefing materials prior to Advisory Committee meeting for Victoza® label update novonordisk.com ↗ |
| 2017-02-02 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Confirms Generic Victoza® Patent Challenge in the United States tevapharm.com ↗ |
| 2016-10-25 | Novo Nordisk A/S | Novo Nordisk indsender ansøgning til registreringsmyndighederne om inkludering af data fra LEADER-studiet i indlægssedlen for Victoza® novonordisk.com ↗ |
| 2016-10-25 | Novo Nordisk A/S | Novo Nordisk submits application to regulatory authorities to include LEADER data in Victoza® label novonordisk.com ↗ |
| 2016-05-20 | Novo Nordisk A/S | FDA offentliggør briefingmateriale forud for møde i rådgivende komite om IDegLira, en kombination af insulin degludec og liraglutid novonordisk.com ↗ |
| 2016-05-20 | Novo Nordisk A/S | FDA posts briefing materials prior to Advisory Committee meeting for IDegLira, a fixed combination product of insulin degludec and liraglutide novonordisk.com ↗ |
| 2016-03-04 | Novo Nordisk A/S | Victoza® reducerer risikoen for alvorlige kardiovaskulære hændelser signifikant i LEADER-studiet novonordisk.com ↗ |
| 2016-03-04 | Novo Nordisk A/S | Victoza® significantly reduces the risk of major adverse cardiovascular events in the LEADER trial novonordisk.com ↗ |
| 2015-08-24 | Novo Nordisk A/S | Novo Nordisk afslutter andet og sidste fase 3a-studie med liraglutid som tillægsbehandling til insulin ved behandling af type 1-diabetes (NN9211) novonordisk.com ↗ |
| 2015-08-24 | Novo Nordisk A/S | Novo Nordisk completes second and final phase 3a trial with liraglutide as adjunct therapy to insulin for people with type 1 diabetes (NN9211) novonordisk.com ↗ |
| 2015-03-23 | Novo Nordisk A/S | Novo Nordisk A/S: Saxenda® godkendt i Europa til behandling af fedme novonordisk.com ↗ |
| 2015-03-23 | Novo Nordisk A/S | Novo Nordisk A/S: Saxenda® approved in Europe for the treatment of obesity novonordisk.com ↗ |
| 2015-01-22 | Novo Nordisk A/S | Novo Nordisk receives positive opinion from the European regulatory authorities for Saxenda® (liraglutide 3 mg) for the treatment of obesity novonordisk.com ↗ |
| 2015-01-22 | Novo Nordisk A/S | Novo Nordisk får positiv udtalelse fra de europæiske registreringsmyndigheder for Saxenda® (liraglutid 3 mg) til behandling af fedme novonordisk.com ↗ |
| 2014-12-23 | Novo Nordisk A/S | Novo Nordisk får FDA-godkendelse for Saxenda® til behandling af fedme novonordisk.com ↗ |
| 2014-12-23 | Novo Nordisk A/S | Novo Nordisk receives FDA approval for Saxenda® for the treatment of obesity novonordisk.com ↗ |
| 2014-09-11 | Novo Nordisk A/S | FDA's rådgivende komite anbefaler godkendelse af Saxenda® til behandling af fedme med stemmerne 14-1 novonordisk.com ↗ |
| 2014-09-11 | Novo Nordisk A/S | Saxenda® for the treatment of obesity receives positive 14-1 vote in favour of approval from FDA Advisory Committee novonordisk.com ↗ |
| 2014-09-09 | Novo Nordisk A/S | FDA offentliggør briefingmateriale forud for mødet i den rådgivende komite om Saxenda® til behandling af fedme novonordisk.com ↗ |
| 2014-09-09 | Novo Nordisk A/S | FDA posts briefing materials prior to Advisory Committee meeting for Saxenda® for the treatment of obesity novonordisk.com ↗ |
| 2014-05-20 | Novo Nordisk A/S | FDA berammer møde i rådgivende komite om liraglutid 3 mg til behandling af fedme novonordisk.com ↗ |
| 2014-05-20 | Novo Nordisk A/S | FDA schedules Advisory Committee meeting for liraglutide 3 mg for the treatment of obesity novonordisk.com ↗ |
| 2013-12-20 | Novo Nordisk A/S | Novo Nordisk indsender registreringsansøgning for liraglutid 3 mg til behandling af fedme novonordisk.com ↗ |
| 2013-12-20 | Novo Nordisk A/S | Novo Nordisk files for regulatory approval of liraglutide 3 mg for the treatment of obesity novonordisk.com ↗ |
| 2013-05-23 | Novo Nordisk A/S | Novo Nordisk rapporterer 8% vægttab i fase 3a-fedmestudie med liraglutid 3 mg novonordisk.com ↗ |
| 2013-05-23 | Novo Nordisk A/S | Novo Nordisk reports 8% weight loss in phase 3a obesity trial with liraglutide 3 mg novonordisk.com ↗ |
| 2013-03-18 | Novo Nordisk A/S | Type 2-diabetikere opnår 6% vægttab med liraglutid 3 mg i fase 3a-fedmestudie novonordisk.com ↗ |
| 2013-03-18 | Novo Nordisk A/S | People with type 2 diabetes achieve 6% weight loss with liraglutide 3 mg in phase 3a obesity trial novonordisk.com ↗ |
| 2012-04-06 | Novo Nordisk A/S | Victoza® label in the US updated to include data showing superior efficacy when compared to Januvia® novonordisk.com ↗ |
| 2012-04-06 | Novo Nordisk A/S | Indlægsseddel for Victoza® i USA opdateret med data, som viser, at Victoza® virker bedre end Januvia® novonordisk.com ↗ |
| 2011-03-15 | Novo Nordisk A/S | Novo Nordisk opnår godkendelse af Victoza® i Kina novonordisk.com ↗ |
| 2011-03-15 | Novo Nordisk A/S | Novo Nordisk receives approval for Victoza® in China novonordisk.com ↗ |
| 2010-06-22 | Novo Nordisk A/S | Novo Nordisk genoptager fase 3-udviklingsprogram for liraglutid til behandling af fedme novonordisk.com ↗ |
| 2010-06-22 | Novo Nordisk A/S | Novo Nordisk re-initiates phase 3 development of liraglutide for obesity novonordisk.com ↗ |
| 2010-01-26 | Novo Nordisk A/S | Novo Nordisk modtager godkendelse for Victoza® (liraglutid) i USA til behandling af type 2-diabetes novonordisk.com ↗ |
| 2010-01-26 | Novo Nordisk A/S | Novo Nordisk receives US approval for Victoza® (liraglutide) for the treatment of type 2 diabetes novonordisk.com ↗ |
| 2010-01-20 | Novo Nordisk A/S | Novo Nordisk får markedsføringstilladelse for Victoza® i Japan novonordisk.com ↗ |
| 2010-01-20 | Novo Nordisk A/S | Novo Nordisk receives approval for Victoza® in Japan novonordisk.com ↗ |
| 2009-12-30 | Novo Nordisk A/S | Opdateret status om tidspunktet for FDA's formelle tilbagemelding om liraglutid novonordisk.com ↗ |
| 2009-12-30 | Novo Nordisk A/S | Update on timeline for formal feedback on liraglutide from the FDA novonordisk.com ↗ |
| 2009-09-23 | Novo Nordisk A/S | Opdateret status om tidspunktet for FDA's formelle tilbagemelding om liraglutid novonordisk.com ↗ |
| 2009-09-23 | Novo Nordisk A/S | Update on timeline for formal feedback on liraglutide from the FDA novonordisk.com ↗ |
| 2009-07-03 | Novo Nordisk A/S | Novo Nordisks Victoza® (liraglutid) får markedsføringstilladelse i Europa novonordisk.com ↗ |
| 2009-07-03 | Novo Nordisk A/S | Novo Nordisk's Victoza® (liraglutide) receives marketing authorisation in Europe novonordisk.com ↗ |
| 2009-04-23 | Novo Nordisk A/S | Novo Nordisk receives positive opinion on Victoza® (liraglutide) from the European regulatory authorities novonordisk.com ↗ |
| 2009-04-23 | Novo Nordisk A/S | Novo Nordisk modtager positiv udtalelse om Victoza® (liraglutide) fra de europæiske registreringsmyndigheder novonordisk.com ↗ |
| 2009-04-02 | Novo Nordisk A/S | Status for mødet i FDA's rådgivende komite om liraglutide til behandling af type 2-diabetes novonordisk.com ↗ |
| 2009-04-02 | Novo Nordisk A/S | Update on FDA Advisory Committee meeting on liraglutide for the treatment of type 2 diabetes novonordisk.com ↗ |
| 2009-03-31 | Novo Nordisk A/S | Briefingdokumenterne om liraglutide til mødet i FDA's rådgivende komite den 2. april er nu tilgængelige novonordisk.com ↗ |
| 2009-03-31 | Novo Nordisk A/S | Liraglutide briefing documents now available for the FDA Advisory Committee meeting on 2 April novonordisk.com ↗ |
| 2008-11-18 | Novo Nordisk A/S | FDA meddeler ny dato for møde i rådgivende komite om liraglutide - samlet tidsplan forventes ikke ændret novonordisk.com ↗ |
| 2008-11-18 | Novo Nordisk A/S | FDA reschedules Advisory Committee meeting for liraglutide - no change of review timeline anticipated novonordisk.com ↗ |
| 2008-09-05 | Novo Nordisk A/S | FDA berammer møde i rådgivende komite om liraglutide novonordisk.com ↗ |
| 2008-09-05 | Novo Nordisk A/S | FDA schedules Advisory Committee meeting for liraglutide novonordisk.com ↗ |
| 2008-07-15 | Novo Nordisk A/S | Novo Nordisk indsender registreringsansøgning for liraglutide i Japan novonordisk.com ↗ |
| 2008-07-15 | Novo Nordisk A/S | Novo Nordisk files for regulatory approval of liraglutide in Japan novonordisk.com ↗ |
| 2008-06-16 | Novo Nordisk A/S | Signifikant vægttab fastholdes hos svært overvægtige efter behandling med liraglutide i et år novonordisk.com ↗ |
| 2008-06-16 | Novo Nordisk A/S | Significant weight loss sustained in obese people treated with liraglutide for one year novonordisk.com ↗ |
| 2008-06-06 | Novo Nordisk A/S | Klinisk studie viser, at liraglutide giver statistisk signifikant bedre blodsukkerregulering end exenatide novonordisk.com ↗ |
| 2008-06-06 | Novo Nordisk A/S | Clinical study shows liraglutide provides statistically significantly better blood glucose control than exenatide novonordisk.com ↗ |
| 2008-05-23 | Novo Nordisk A/S | Novo Nordisk files for regulatory approval of liraglutide in both the US and Europe novonordisk.com ↗ |
| 2008-05-23 | Novo Nordisk A/S | Novo Nordisk indsender registreringsansøgning for liraglutide i USA og Europa novonordisk.com ↗ |
| 2007-12-11 | Novo Nordisk A/S | Final phase 3 study confirms very favourable effect of liraglutide on blood glucose control and body weight novonordisk.com ↗ |
| 2007-12-11 | Novo Nordisk A/S | Afsluttende fase 3-studie bekræfter, at liraglutide har en overbevisende effekt på blodsukkerregulering og vægt novonordisk.com ↗ |
| 2007-11-20 | Novo Nordisk A/S | Nyt fase 2-studie viser, at liraglutide medfører signifikant vægttab hos svært overvægtige novonordisk.com ↗ |
| 2007-11-20 | Novo Nordisk A/S | New phase 2 study shows that liraglutide leads to significant weight loss in obese people novonordisk.com ↗ |
| 2007-09-14 | Novo Nordisk A/S | Fase 3-studie bekræfter, at behandling med liraglutide sænker både blodsukker og vægt med lav risiko for hypoglykæmi novonordisk.com ↗ |
| 2007-09-14 | Novo Nordisk A/S | Phase 3 study confirms that liraglutide treatment leads to both glucose and weight reduction with a low risk of hypoglycaemic events novonordisk.com ↗ |
| 2007-08-20 | Novo Nordisk A/S | Liraglutide forbedrer blodsukkerregulering og medfører vægttab, viser to fase 3-studier med mere end 2.000 patienter novonordisk.com ↗ |
| 2007-08-20 | Novo Nordisk A/S | Liraglutide improves glucose control and lowers body weight in two phase 3 studies comprising more than 2,000 patients novonordisk.com ↗ |
| 2007-06-21 | Novo Nordisk A/S | Liraglutide giver en væsentligt bedre blodsukkerregulering end insulin glargine i fase 3-studie novonordisk.com ↗ |
| 2007-06-21 | Novo Nordisk A/S | Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study novonordisk.com ↗ |
| 2005-11-25 | Novo Nordisk A/S | Promising clinical results from liraglutide phase 2b study novonordisk.com ↗ |
| 2005-11-25 | Novo Nordisk A/S | Lovende kliniske resultater fra fase 2b-studiet med liraglutide novonordisk.com ↗ |
Evidence & citations 24 cited values
Every value below carries the sentence it was read from. 428 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Liraglutide | “Subjects in Liraglutide 3.0 group will receive Saxenda® plus behavioral weight loss counselling to portion control to achieve 500 kcal daily deficit based on MedGem required...” NCT03795701 ↗399“The objective of this study is to investigate the influence of T2DM susceptibility gene polymorphisms (NOS1AP, KCNQ1, TCF7L2, WSF1, GLP-1R, etc.) on the efficacy of GLP-1 RA...” NCT06256419 ↗ “Subjects will receive a glucagon-like peptide 1 receptor agonist (either semaglutide, tirzepatide or liraglutide) by self-injection or orally (semaglutide or orforglipron) for...” NCT07107334 ↗ “The combination of insulin degludec (100 units/mL) and liraglutide (3.6 mg/mL), termed IDegLira, was approved in 2014 for the treatment of type 2 diabetes inadequately...” NCT04190160 ↗ “AIMS: β-cell stress and dysfunction may contribute to islet autoimmunity and progression to clinical type 1 diabetes. We present a protocol of three randomised controlled...” PMID 35797241 ↗ Jul 2022 “Liraglutide injection,developed and marketed as Victoza® by Novo Nordisk,is indicated for the treatment of patients with type 2 diabetes and was approved by the U.S. Food and...” NCT04373967 ↗ “Three incretin-based medications that have been approved for treatment of obesity including liraglutide, semaglutide, or tirzepatide will be used in the nonsurgical group.” NCT06374875 ↗ “Chemical Name: GLP-1 Receptor Agonists (GLP1RA) (e.g., Exenatide, Liraglutide, Dulaglutide, Semaglutide) Class: Glucagon-Like Peptide-1 Receptor Agonists” NCT06449235 ↗ “In this study, patients received standard clinical doses (e.g., liraglutide 1.2-1.8 mg once daily or semaglutide 0.5-1.0 mg once weekly) for 6 months.” NCT07539584 ↗ “Liraglutide, a GLP-1 analogue, was reported to reduce cardiac rupture and infarct size and improve cardiac output in normal and diabetic mice.” NCT02577848 ↗ “Clinical trials had verified that good metabolic control would be achieved when Liraglutide (GLP-1) was added to the conventional therapies.” NCT01954147 ↗ “The choice of AOMs considered may include metformin, topiramate, liraglutide, dulaglutide, semaglutide, tirzepatide, and empagliflozin.” NCT07027969 ↗ “Efficacy of Vildagliptin, Liraglutide and Empagliflozin in the Management of Fatty Liver Disease Among Patients With Type 2 Diabetes” NCT05041673 ↗ “This is a randomized, double-blinded, placebo-controlled trial of liraglutide versus placebo over a follow-up period of 12 months” NCT03048578 ↗ “Liraglutide is a Glucagon-like peptide-1 (GLP-1) analogue shown to be effective in the treatment of type 2 Diabetes Mellitus.” NCT01208012 ↗ “Liraglutide will be administered by subcutaneous injection taken by subjects beginning at a dose at 0.6 mg nightly” NCT05681299 ↗ “GLP-1 Receptor Agonist(e.g. exenatide, liraglutide) have the effects of lowering blood sugar and weight control” NCT03151005 ↗ “Subjects with preclinical type 1 diabetes aged 18-30 years are treated with Victoza® (liraglutide)” NCT02611232 ↗ “then liraglutide 0.6 mg once daily (with a subsequent increases to 1.2 mg and 1.8 mg once daily).” NCT01974544 ↗ “Liraglutide 1.2 mg QD s.c. was added after first two weeks of monotherapy with MET.” NCT03353948 ↗ “Liraglutide: 6 mg/ml Semaglutide: 1.34 mg/ml Dulaglutide: de 0.75 mg ou 1.5 mg” NCT03498001 ↗ “Compared With Once-Daily Liraglutide 3 mg in Adult Participants With Obesity” NCT05111912 ↗ “Liraglutide 3.0 mg (Saxenda® injections, subcutaneously \[under the skin\])” NCT03799198 ↗ “subgroup 5A- addition of liraglutide 1,2-1,8 mg/day” NCT03804411 ↗ “Incretin analogues: Liraglutide up to 1.8 mg daily” NCT02041234 ↗ “Liraglutide, Victoza or Exenatide, Byetta.” NCT01687582 ↗ “Liraglutide were taken daily for 3 months” NCT02650596 ↗ “Dulaglutide, liraglutide, semaglutide” NCT05390892 ↗ “liraglutide 1.8 mg per day” NCT04135287 ↗ “Single dose of Liraglutide” NCT02777073 ↗ “liraglutide (0.6 mg/day)” NCT04027023 ↗ “- liraglutide (Victoza®)” NCT02244164 ↗ “Liraglutide (Vicotza)” NCT01677104 ↗ “liraglutide (Victoza)” NCT07325435 ↗ “Liraglutide (Saxenda)” NCT05812183 ↗ “Liraglutide” NCT02041234 ↗ |
| Known as | - liraglutide (Victoza) | “- liraglutide (Victoza®)” NCT02244164 ↗1“liraglutide (Victoza)” NCT07325435 ↗ |
| Known as | 4P004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07225829 ↗ |
| Known as | CinnaGen-liraglutide | “CinnaGen-liraglutide (Liraglutide 6 MG/ML Pen Injector by CinnaGen Company) will be administered 1.8 mg/day subcutaneously.” NCT03421119 ↗ |
| Known as | LIRA | “The purpose of the trial is to investigate the effect of insulin degludec (IDeg) in combination with liraglutide (Lira) and metformin (at least 1500 mg daily or maximum...” NCT01664247 ↗5“AIM: Two treatment strategies were compared in patients with type 2 diabetes (T2DM) on basal insulin requiring intensification: addition of once-daily (OD) liraglutide (Lira)...” PMID 24443830 ↗ Feb 2014 “OBJECTIVE: To observe the effect of liraglutide (LIRA) in combination of umbilical cord mesenchymal stem cells (hUC-MSCs) in treating type 2 diabetes mellitus.” PMID 27143183 ↗ May 2016 “liraglutide 1.2 mg/day (LIRA), 2) canagliflozin 100 mg/day (CANA), or 3) liraglutide 1.2 mg plus canagliflozin 100 mg (CANA/LIRA) for 16 weeks.” PMID 32220916 ↗ Mar 2020 “Liraglutide (LIRA) in dose of 3 mg was recently approved as an anti-obesity drug.” NCT02909933 ↗ “using the GLP-1 analog liraglutide (LIRA) as a comparator in T2DM.” PMID 29545266 ↗ Mar 2018 |
| Known as | LIRA 3 mg | “To study the efficacy and safety of the GLP-1 analog liraglutide 3 mg (LIRA 3 mg) vs. placebo (PL) for reduction of body weight (BW) and hyperandrogenism in women with...” PMID 35710599 ↗ Jun 2022 |
| Known as | Liraglutid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03961659 ↗ |
| Known as | Liraglutida | ChEMBL registry synonym — accepted as the source's own label CHEMBL4084119 ↗ |
| Known as | Liraglutide (rdna origin) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4084119 ↗ |
| Known as | Liraglutide (Vicotza) | “Liraglutide (Vicotza)” NCT01677104 ↗ |
| Known as | Liraglutide component of xultophy 100/3.6 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4084119 ↗ |
| Known as | Liraglutide recombinant | ChEMBL registry synonym — accepted as the source's own label CHEMBL4084119 ↗ |
| Known as | liraglutide\_obesity | “Patients will receive subcutaneous injections of Saxenda 18 mg/3 mL Pen (liraglutide\_obesity) starting at 0.6 mg qd.” NCT06217848 ↗ |
| Known as | Melitide | “The aim of this study was to compare the efficacy and safety of a biosimilar liraglutide (Melitide®; CinnaGen, Tehran, Iran) to the reference liraglutide (Victoza®; Novo...” PMID 37707701 ↗ Sep 2023 |
| Known as | NN-9924 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4084119 ↗ |
| Known as | NN2211 | “This was a randomized, double-blind, parallel-group, placebo-controlled trial investigating the effect of the long-acting GLP-1 derivative liraglutide (NN2211) on glycemic...” PMID 15277417 ↗ Aug 20043“We explored the effect of short-term (1 week) treatment with a GLP-1 derivative, liraglutide (NN2211), on 24-h dynamics in glycemia and circulating free fatty acids, islet cell...” PMID 15111485 ↗ May 2004 “after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.” PMID 15161785 ↗ Jun 2004 “Liraglutide (NN2211) is a long-acting GLP-1 analogue” PMID 16026367 ↗ Aug 2005 |
| Known as | NNC 90-1170 | “A Randomised, Double-blind Within Dose Group, Single-centre, Placebo-controlled, Parallel 2-different Dose Group, 14-day Multiple s.c. Doses Study to Assess the Safety,...” NCT01615978 ↗5“A Randomised, Double-blind, Single-centre, Placebo-controlled, 21-day Multiple s.c. Doses, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and...” NCT01620476 ↗ “NNC 90-1170 (liraglutide) added to metformin compared to metformin given alone” NCT01511172 ↗ “NNC 90-1170 (liraglutide)” NCT01507272 ↗ “NNC 90-1170 (liraglutide)” NCT01620463 ↗ |
| Known as | Saxenda | “Liraglutide, a glucagon-like peptide-1 analog, approved for the treatment of obesity at the dose of 3 mg per day and commercialized under the name of Saxenda, was proved to...” NCT03534310 ↗22“Dose titration Saxenda (from 0.6 mg to 3.0 mg liraglutide once daily), should take place during the first 4 weeks after randomisation as described: Dose Escalation Schedule of...” NCT05111912 ↗ “Other acceptable, less preferrable, options: liraglutide (Saxenda or Victoza), semaglutide tablet (Rybelsus), or lower dose of tirzepatide and semaglutide injections.” NCT06374875 ↗ “after daily subcutaneous injections of Saxenda® (liraglutide 3.0 mg) or Placebo by pen injector.” NCT03347890 ↗ “The aim of the study is to investigate the effects of preoperative Saxenda (liraglutide).” NCT06865365 ↗ “Liraglutide 3.0 mg (Saxenda® injections, subcutaneously \[under the skin\])” NCT03799198 ↗ “Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml” NCT07590219 ↗ “Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml” NCT03279731 ↗ “Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml” NCT04186494 ↗ “Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml” NCT03520062 ↗ “liraglutide 3 mg (Saxenda®) once-daily” NCT04781998 ↗ “Liraglutide Pen Injector [Saxenda]” NCT05285397 ↗ “Drug: Liraglutide 3 mg (Saxenda)” NCT02905864 ↗ “Drug: Liraglutide 3 mg (Saxenda)” NCT02931383 ↗ “Drug: Liraglutide 3 mg (Saxenda)” NCT02928679 ↗ “Liraglutide 6 MG/ML [Saxenda]” NCT04575194 ↗ “Liraglutide 3 mg (Saxenda)” NCT02910570 ↗ “Liraglutide 3 mg (Saxenda)” NCT02928614 ↗ “Liraglutide (Saxenda)” NCT05812183 ↗ |
| Known as | Victoza | “Victoza® is supplied in pens for injection containing 18 mg of the GLP-1 agonist liraglutide in 3 mL sterile water with disodiumphosphate and propylene glycol, and phenol for...” NCT01451905 ↗31“Victoza® is supplied in pens for injection containing 18 mg of the GLP-1 agonist liraglutide in 3 mL sterile water with disodiumphosphate and propylenglycol, and phenol for...” NCT01460069 ↗ “This study aimed to evaluate the pharmacokinetics (PKs), safety, and immunogenicity of the biosimilar (RD12014) compared to reference liraglutide (Victoza) in healthy Chinese...” PMID 35871497 ↗ Jul 2022 “Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes” NCT02730377 ↗ “The study seeks to document the utility of a SL formulation of the approved active ingredient liraglutide, currently marketed in a subcutaneous (SC) formulation as Victoza®.” NCT05268237 ↗ “Other acceptable, less preferrable, options: liraglutide (Saxenda or Victoza), semaglutide tablet (Rybelsus), or lower dose of tirzepatide and semaglutide injections.” NCT06374875 ↗ “Liraglutide 1.8 mg (Victoza), starting with 2-week dose escalation, was administered subcutaneously once daily as an open-label reference arm.” PMID 28768173 ↗ Aug 2017 “liraglutide developed by Novo Nordisk (Victoza®) also has beneficial effects in type 2 diabetes mellitus as has been proven by several trials” NCT01638260 ↗ “To date, 2 publications have evaluated the safety profile and efficacy of an aGLP1, liraglutide (Victoza®), in diabetic dialysis patients.” NCT04529278 ↗ “Liraglutide (Victoza) is an acylated analogue of glucagon-like peptide-1 (GLP-1) indicated for the treatment of type 2 diabetes mellitus” NCT02014740 ↗ “Effects of Victoza® (Liraglutide) Versus Lyxumia® (Lixisenatide) on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion” NCT02231658 ↗ “A Phase 1 Study of Liraglutide Injection and Victoza® in Healthy Chinese Subjects: An Open, Randomized, Single-Dose and Crossover Study” NCT05225974 ↗ “Liraglutide (Victoza®), a human glucagon-like peptide-1 (GLP-1) analogue, improves glycaemic control and reduces weight.” NCT01392898 ↗ “Victoza® (Liraglutide 6 MG/ML Pen Injector by Novo Nordisk Company) will be administered 1.8 mg/day subcutaneously.” NCT03421119 ↗ “Liraglutide (Victoza ®), human GLP-1 analog produced using recombinant DNA technology in saccharomyces cerevisiae.” NCT01469351 ↗ “Subjects with preclinical type 1 diabetes aged 18-30 years are treated with Victoza® (liraglutide)” NCT02611232 ↗ “Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and Blood” NCT02650206 ↗ “pre-trial treatment of liraglutide (Victoza®) (GLP-1 receptor agonist) + OAD” NCT01676116 ↗ “Liraglutide ("Victoza"), subcutaneous 1,8 mg once daily for 180 days” NCT02473809 ↗ “single dose of Victoza ( liraglutide) 1.8 mg” NCT02777073 ↗ “Liraglutide, Victoza or Exenatide, Byetta.” NCT01687582 ↗ “Liraglutide Pen Injector [Victoza]” NCT03371862 ↗ “Liraglutide Pen Injector [Victoza]” NCT03260881 ↗ “Liraglutide Pen Injector [Victoza]” NCT04057261 ↗ “Liraglutide 6 MG/ML [Victoza]” NCT04324229 ↗ “Victoza® (liraglutide)” NCT02908087 ↗ |
| Known as | Victoza (liraglutide) | “Victoza (liraglutide)” NCT03010683 ↗ |
| Action | Activate | “The glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide” PMID 22174428 ↗ Dec 2011 |
| Modality | Peptide | “Liraglutide, a once-daily human glucagon-like peptide-1 analogue” PMID 18201212 ↗ Jan 2008 |
| Route | Other | “Liraglutide or placebo is administered by injection once daily in the evening.” NCT00154401 ↗ |
| Target | GLP1R | “OBJECTIVE: The efficacy and safety of adding liraglutide (a glucagon-like peptide-1 receptor agonist) to metformin were compared with addition of placebo or glimepiride to...” PMID 18931095 ↗ Oct 2008 |